High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity
- 1 January 1976
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 2 (3) , 319-325
- https://doi.org/10.1002/mpo.2950020313
Abstract
In clinical studies performed during 111 infusions of high dose methotrexate (MTX) we have evolved a clinical and laboratory protocol which permits such therapy without prohibitive risk to the patient. The plasma MTX data obtained indicate that pharmacokinetic disposition is dose related during these infusions and that such data are useful in identifying patients at risk from serious toxicity.Keywords
This publication has 8 references indexed in Scilit:
- Competitive protein binding assay for methotrexate.Proceedings of the National Academy of Sciences, 1975
- The integration of chemotherapy into a combined modality approach to cancer therapy: V. Squamous cell cancer of the head and neckCancer Treatment Reviews, 1975
- Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapyCancer, 1975
- Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic SarcomaNew England Journal of Medicine, 1974
- High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcomaCancer, 1974
- Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancerCancer, 1972
- THE CHARACTERISTICS OF THE MEMBRANE TRANSPORT OF AMETHOPTERIN AND THE NATURALLY OCCURRING FOLATESAnnals of the New York Academy of Sciences, 1971
- MethotrexatePublished by Springer Nature ,1970